RESEARCH TRIANGLE PARK – The new chief financial officer of robotic surgery firm TransEnterix could obtain as many as 200,000 shares in the company as part of an inducement grant.

Shameze Rampertab came onboard as CFO effective August 24.

The stock plan, according to the company:

  • Non-qualified stock options to acquire 150,000 shares of the Company’s common stock at an exercise price per share of $0.42, which was equal to the closing price on August 24, 2020, Mr. Rampertab’s first day of employment. The stock options vest one-third annually on each of April 24, 2021, 2022 and 2023.
  • 30,000 time-based restricted stock units (“RSUs”). The time-based RSUs will vest over three years, one-third each year on July 1, 2021, 2022 and 2023
  • 20,000 performance-based RSUs. The performance-based RSUs (the “PRSUs”) will have time-based vesting over three years, one-third each year on July 1, 2021, 2022, and 2023 and are also subject to vesting upon the achievement of a delineated performance goal.